VABOMERE
Total Payments
$1.1M
Transactions
2,190
Doctors
889
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $48,046 | 35 | 26 |
| 2018 | $114,297 | 137 | 43 |
| 2017 | $917,322 | 2,018 | 843 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $422,733 | 184 | 39.2% |
| Honoraria | $286,941 | 171 | 26.6% |
| Consulting Fee | $176,294 | 32 | 16.3% |
| Travel and Lodging | $76,820 | 323 | 7.1% |
| Food and Beverage | $72,138 | 1,467 | 6.7% |
| Education | $41,714 | 11 | 3.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,525 | 1 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $500.00 | 1 | 0.0% |
Payments by Type
General
$656,932
2,006 transactions
Research
$422,733
184 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EFFICACY, SAFETY, TOLERABILITY OF CARBAVANCE COMPARED TO BEST AVAILABLE THERAPY IN SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTEROBACTERIACEAE, IN ADULTS | The Medicines Company | $139,186 | 0 |
| OPEN LABEL, DOSE-FINDING, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF MEROPENEM-VABORBACTAM IN PEDIATRIC SUBJECTS WITH SERIOUS BACTERIAL INFECTIONS | The Medicines Company | $85,477 | 1 |
| A STUDY OF MEROPENEM-VABORBACTAM VERSUS PIPERACILLINTAZOBACTAM IN PARTICIPANTS WITH HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA | The Medicines Company | $36,562 | 1 |
| Susceptibility to meropenem-vaborbactam and comparator agents in relation to clonal background among international carbapenem-resistant Escherichia coli clinical isolates | Melinta Therapeutics, Inc. | $36,160 | 0 |
| Carbavance RPX2014RPX7009 Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae | The Medicines Company | $30,356 | 0 |
| REMPEX-507 | Melinta Therapeutics, Inc. | $9,499 | 0 |
| EFFICACY, SAFETY, TOLERABILITY OF MEROPENEM-VABORBACTAM COMPARED TO PIPERACILLIN-TAZOBACTAM IN COMPLICATED URINARY TRACT INFECTIONS CUTIS, INCLUDING ACUTE PYELONEPHRITIS AP, IN ADULTS | The Medicines Company | $4,336 | 0 |
| An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study Of A Single Dose Infusion of Meropenem-Vaborbactam in Pediatric Subjects Less Than 18 Years of Age with Selected Serious Bacterial Infections | The Medicines Company | $850.00 | 0 |
Top Doctors Receiving Payments for VABOMERE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Infectious Disease | Bridgeport, WV | $7,113 | 10 |
| , M.D | Infectious Disease | El Paso, TX | $6,666 | 18 |
| , MD | Internal Medicine | Detroit, MI | $6,559 | 14 |
| , MD | Infectious Disease | Altamonte Springs, FL | $6,501 | 18 |
| , M.D | Infectious Disease | Boston, MA | $6,142 | 9 |
| , MD | Infectious Disease | West Covina, CA | $5,806 | 7 |
| , M.D | Infectious Disease | Houston, TX | $5,486 | 15 |
| , M.D | Internal Medicine | Mcallen, TX | $5,461 | 12 |
| , M.D | Internal Medicine | Phoenix, AZ | $5,422 | 10 |
| , M.D | Infectious Disease | Torrance, CA | $5,390 | 10 |
| , MD | Pulmonary Disease | Chicago, IL | $5,389 | 9 |
| , M.D | Infectious Disease | Houston, TX | $5,021 | 12 |
| , MD | Infectious Disease | Portland, OR | $5,000 | 2 |
| , M.D | Infectious Disease | Chicago, IL | $4,862 | 11 |
| William Green | — | Mobile, AL | $4,708 | 9 |
| , M.D | Infectious Disease | Detroit, MI | $4,653 | 7 |
| , MD | Pediatric Emergency Medicine | Cleveland, OH | $4,538 | 3 |
| , M.D | Infectious Disease | Sylmar, CA | $4,504 | 12 |
| , MD | Internal Medicine | Whitesburg, KY | $4,420 | 16 |
| , MD | Internal Medicine | Boston, MA | $4,416 | 12 |
| , M.D | Infectious Disease | Houston, TX | $4,359 | 11 |
| , M.D | Pulmonary Disease | Phoenix, AZ | $4,048 | 5 |
| , M.D | Infectious Disease | Randolph, NJ | $3,950 | 11 |
| , MD | Infectious Disease | Memphis, TN | $3,929 | 5 |
| , MD | Infectious Disease | Madison, WI | $3,905 | 8 |
Ad
Manufacturing Companies
- The Medicines Company $1.0M
- Melinta Therapeutics, Inc. $48,046
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 889
- Transactions 2,190
About VABOMERE
VABOMERE is a drug associated with $1.1M in payments to 889 healthcare providers, recorded across 2,190 transactions in the CMS Open Payments database. The primary manufacturer is The Medicines Company.
Payment data is available from 2017 to 2019. In 2019, $48,046 was paid across 35 transactions to 26 doctors.
The most common payment nature for VABOMERE is "Unspecified" ($422,733, 39.2% of total).
VABOMERE is associated with 8 research studies, including "EFFICACY, SAFETY, TOLERABILITY OF CARBAVANCE COMPARED TO BEST AVAILABLE THERAPY IN SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTEROBACTERIACEAE, IN ADULTS" ($139,186).